Connor, Clark & Lunn Investment Management (CC&L)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,827	Closed	-$411K	–	1570
2023 Q1	$411K	Sell	3,827 -8,947	-70%	-$1.03M	﹤0.01%	937
2022 Q4	$1.41M	Buy	+12,774	New	+$828K	0.01%	621

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RXDX Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,827 shares — an estimated $411K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.41M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 3,827 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $411K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Prometheus Biosciences, Inc. Common Stock position peaked at $1.41M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.